Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: A 6-month follow-up study

Xenobiotica

Volumn 38, Issue 6, 2008, Pages 641-651

  Ngow, H ^a   Teh, L K ^b   Langmia, I M ^b   Lee, W L ^b   Harun, R ^c   Ismail, R ^d   Salleh, M Z ^b  

^a INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^c UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^d INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

Author keywords

CYP2C9; CYP2C9*1 *1; CYP2C9*1 *3; Ethnicity; Life threatening bleeding; Malaysian pharmacodiagnostics; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; DNA; WARFARIN;

ADULT; ALLELE; ARTICLE; BLEEDING; BLOOD; CHINESE; CLINICAL PRACTICE; DNA EXTRACTION; FEMALE; FOLLOW UP; GENOTYPE; HEART ATRIUM FIBRILLATION; HOSPITAL; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MEDICAL RECORD REVIEW; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; VEIN THROMBOSIS;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CHINA; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEMORRHAGE; HUMANS; MALAYSIA; MALE; MIDDLE AGED; PHARMACOGENETICS; RETROSPECTIVE STUDIES; WARFARIN;

EID: 45849121412     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250801999087     Document Type: Article

References (18)

1. Aithal GP, Day CP, Kesteven PJL, Daly AK. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154):717-719.
2. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. 1994. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343:499-503.
3. Beyth RJ, Quinn L, Landefeld CS. 2000. A multi-component intervention to prevent major bleeding complications in older patients receiving warfarin. Annals of Internal Medicine 133:687-695.
4. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, et al. 2005. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinant of acenocoumaraol sensitivity. Blood 106:135-140.
5. Cannegieter SC, Rosendaal FR, Wintzen AR, Van der Meer FJ, Vandenbroucke JP, Briet E. 1995. Optimal oral anticoagulant therapy in patients with mechanical heart valves. New England Journal of Medicine 333:11-17.
6. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. 2005. A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 105:645-649.
7. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH. 1993. Risk factors for complications of chronic anticoagulation. Annals of Internal Medicine 118:511-520.
8. Hirsch J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J. 1998. Oral anticoagulants: Mechanisms of action, clinical effectiveness and optimal therapeutic range. Chest 114:445S-469S.
9. Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM. 2004. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clinical Pharmacology and Therapy 75:198-203.
10. Poller L, Shiach CR, MacCallum PK, Johansen AM, Münster AM, Magalhães A, Jespersen J. 1998. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 352:1505-1509.
11. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, et al. 2004. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-541.
12. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. 2005. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 106:2329-2333.
13. Stroke Prevention in Atrial Fibrillation Investigators. 1996a. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348:633-638.
14. Stroke Prevention in Atrial Fibrillation Investigators. 1996b. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Archives of Internal Medicine 156:409-416.
15. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H. 1998a. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clinical Pharmacology and Therapy 63:519-528.
16. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H. 1998b. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8:365-373.
17. Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, Rahman AR. 2001. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. Journal of Clinical Pharmacology and Therapy 26:205-211.
18. Zainuddin Z, Teh LK, Suhaimi AWM, Ismail R. 2006. Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism. Journal of Clinical Pharmacology and Therapy 31:187-191.